MedTrace Logo

A Safety and Tolerability Evaluation of Two 10-Week Dose Regimens of Orally-Administered PF-04494700 in Alzheimer's Patients

NCT00141661 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 67

Last updated 2009-08-20

No results posted yet for this study

Summary

A 10-week safety and tolerability study of a potential treatment for mild to moderate Alzheimer's disease.

Conditions

  • Alzheimer Disease

Interventions

DRUG

PF-04494700 - Low Dose Arm

30 mg loading dose for 6 days, followed by 10 mg daily

DRUG

PF-04494700 - High Dose Arm

60 mg loading dose for 6 days, followed by 20 mg daily

DRUG

Placebo Comparator

Matching placebo.

Sponsors & Collaborators

  • Trans Tech Pharmaceuticals

    collaborator UNKNOWN

  • Pfizer

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-10-31
Primary Completion
2006-06-30
Completion
2006-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00141661 on ClinicalTrials.gov